iBio, Inc. Common Stock Total Assets
iBio, Inc. Common Stock total assets. Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) holds total assets worth $99.11 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of iBio, Inc. Common Stock for the company's overall valuation and market capitalisation.
Total Assets of iBio, Inc. Common Stock (2007–2026)
Total assets of iBio, Inc. Common Stock from 2007 to 2026. This chart illustrates how iBio, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See IBIO stock price and chart for real-time trading data and today's change.
iBio, Inc. Common Stock - Asset Composition Analysis
iBio, Inc. Common Stock Total Assets Breakdown (June 2026)
iBio, Inc. Common Stock total assets breakdown as of June 2026. iBio, Inc. Common Stock's total assets of $99.11 Million consist of 93.1% current assets and 7.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 56.9% |
| Accounts Receivable | $1.10 Million | 1.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.82 Million | 1.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2026)
This chart illustrates how iBio, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IBIO working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: iBio, Inc. Common Stock's current assets represent 93.1% of total assets in 2026, an increase from 4.7% in 2007.
- Cash Position: Cash and equivalents constituted 56.9% of total assets in 2026, up from 0.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 88.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 1.8% of total assets.
iBio, Inc. Common Stock Competitors by Total Assets
Key competitors of iBio, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
iBio, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.85 | 1.59 | 11.09 |
| Quick Ratio | 7.85 | 1.59 | 11.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $80.48 Million | $3.62 Million | $81.72 Million |
iBio, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between iBio, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.93 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | 327.5% |
| Total Assets | $99.11 Million |
| Market Capitalization | $52.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values iBio, Inc. Common Stock's assets below their book value (0.53x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: iBio, Inc. Common Stock's assets grew by 327.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for iBio, Inc. Common Stock (2007–2026)
The table below shows the annual total assets of iBio, Inc. Common Stock from 2007 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $99.11 Million | +327.47% |
| 2025-06-30 | $23.18 Million | -19.31% |
| 2024-06-30 | $28.73 Million | -30.27% |
| 2023-06-30 | $41.21 Million | -58.55% |
| 2022-06-30 | $99.41 Million | -32.36% |
| 2021-06-30 | $146.97 Million | +56.04% |
| 2020-06-30 | $94.19 Million | +207.95% |
| 2019-06-30 | $30.59 Million | -29.01% |
| 2018-06-30 | $43.08 Million | +19.64% |
| 2017-06-30 | $36.01 Million | -30.21% |
| 2016-06-30 | $51.60 Million | +313.00% |
| 2015-06-30 | $12.49 Million | +92.39% |
| 2014-06-30 | $6.49 Million | -30.58% |
| 2013-06-30 | $9.35 Million | -4.20% |
| 2012-06-30 | $9.76 Million | +33.11% |
| 2011-06-30 | $7.34 Million | +48.79% |
| 2010-06-30 | $4.93 Million | 0.00% |
| 2009-06-30 | $4.93 Million | +38.91% |
| 2008-06-30 | $3.55 Million | -5.81% |
| 2007-06-30 | $3.77 Million | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimiz… Read more